APR 23, 2020 7:54 AM PDT

Doctors, watch out for unexpected side effects in small clinical trials

Doctors who have patients in small-sized clinical trials that test new cancer drugs should be on the look-out for unexpected side effects suggests new research with was published recently in the journal Frontiers in Oncology. Led by medical oncologist, Tejas Patil, MD, and trauma surgeon, Lisa Ferrigno, MD, MPH, FACS, the published case series highlights an emerging trend in oncological clinical trials and warns physicians to be extra alert.

"You have drugs getting out onto the market with fewer numbers involved in terms of testing, so the lay of the land with adverse effects might not be completely hashed out. There are not many people who have taken the drug," explains Ferrigno.

When Patil and Ferrigno first noticed an unanticipated side effect occurring in their patients with lung cancer in a University of Colorado Cancer Center clinical trial, they were surprised. The trial was with the drug osimertinib (Tagrisso), which has shown success as a genetically targeted anti-cancer drug. But what the physicians noticed in their patients was a rare twist in the right side of their colons, a condition known as cecal volvulus

"When your first patient has it, you just think it's a one-off. Then you see it again and see it again, and once you get to your third patient, you start to think it's a pattern. We noticed all these patients were getting the same dose of osimertinib, and it prompted me to think it's not one-off, but a dose-exposure relationship," says Patil.

Interestingly, the doctors noticed that only patients treated with 160mg doses who developed this possible side effect, while those treated with 80mg doses of osimertinib did not.

"Studies show 160mg is a pretty reasonable dose for osimertinib in many cases, so we expect to see this dose used even more, maybe leading to more of this kind of side effect. That's why it's important to start noticing these observations now," Patil says.

Photo: Pixabay

Their observations about this case series serve as an alarm signal for other clinical trials that test drugs on small populations of patients. As Eureka Alert reports, “Smaller studies reduce the likelihood of seeing rare side effects; and so it may fall on clinicians using these drugs after FDA approval to notice medication side effects that went undetected during clinical trials.”

Sources: Frontiers in Oncology, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
NOV 15, 2020
Genetics & Genomics
Novel Cancer-Driving Genes are Discovered
NOV 15, 2020
Novel Cancer-Driving Genes are Discovered
Cells have to be able to divide so new ones can replenish cells that get worn out, dysfunctional, or that accumulate dam ...
DEC 07, 2020
Cancer
Black women with breast cancer have higher rates of mortality and comorbidities
DEC 07, 2020
Black women with breast cancer have higher rates of mortality and comorbidities
New research published today the American Cancer Society’s peer-reviewed journal, Cancer, looks at the mortality r ...
DEC 11, 2020
Cancer
Fan therapy proves to improve breathlessness in patients with advanced cancer
DEC 11, 2020
Fan therapy proves to improve breathlessness in patients with advanced cancer
New research released from Johns Hopkins Kimmel Cancer Center suggests that the air from fans may help patient ...
DEC 28, 2020
Cell & Molecular Biology
How an Herbal Compound May Fight Pancreatic Cancer
DEC 28, 2020
How an Herbal Compound May Fight Pancreatic Cancer
For centuries, Chinese practitioners have used herbs to treat all kinds of ailments. New research has shown that one of ...
JAN 04, 2021
Cancer
The most diverse genetic analysis of prostate cancer to date
JAN 04, 2021
The most diverse genetic analysis of prostate cancer to date
Racial health disparities are glaringly obvious in the case of prostate cancer where the risk level is roughly 75% highe ...
JAN 17, 2021
Cancer
Analyzing the role of our circadian clocks in prostate cancer
JAN 17, 2021
Analyzing the role of our circadian clocks in prostate cancer
Research published recently in Nature Communications looks into the role that circadian rhythms play on prostate cancer ...
Loading Comments...